Posted by Michael Wonder on 12 Oct 2018
Spero Therapeutics receives QIDP designation from the U.S. FDA for the development of SPR206
11 October 2018 - Spero Therapeutics announced today that SPR206, a product candidate within Spero’s Potentiator Platform, has been granted qualified infectious disease product designation by the U.S. FDA for the treatment of complicated urinary tract infections and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
SPR206 is designed as a single agent to treat multi0drug resistant and extensively drug-resistant bacterial strains, including carbapenem-resistant Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae, for which there is a significant unmet medical need. Based on promising results from preclinical toxicology studies for SPR206, Spero plans to initiate a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of SPR206 in 2019.
